Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 According ... Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, ... Manifold, & Rotary) & Geography - Global Trends ... and segments the lyophilization market on the basis ... and projections of the market size of each ...
(Date:9/19/2014)... , Sept. 19, 2014  Pressure BioSciences, Inc. ... it has received and approved all parts required ... and has begun to manufacture the new PCT-based ... will be ready for shipment by mid-October and ... released at a rate of about one per ...
(Date:9/19/2014)... N.Y. , Sept. 19, 2014  BioSpecifics Technologies Corp. ... in class collagenase-based products marketed as XIAFLEX ® in ... today that BioSpecifics, President, Tom Wegman , will present ... NewsMakers in the Biotech Industry Conference. The ... 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... ,GlaxoSmithKline (NYSE: GSK ; LSE) today announced ... granted Priority Review for PROMACTA(R),(eltrombopag) for the short-term ... PROMACTA is an investigational,once-daily oral treatment that induces ... generate platelets, which are critical in minimizing the,incidence ...
... 3 NicOx S.A.,(Euronext Paris: COX) today announced its ... activities during the year. NicOx also,announced today the initiation ... naproxcinod (see separate press release)., Key highlights ... phase 3 trials for naproxcinod ...
Cached Medicine Technology:FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 2FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 3FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 4Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 2Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 3Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 4Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 5Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 6Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 7Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 8Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 9Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 10Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 11Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 12Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 13Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 14Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 15
(Date:9/19/2014)... (PRWEB) September 19, 2014 Top10BestSEOHosting.com ... and announces that HostMonster, Arvixe and Bluehost are ... to buy high quality WordPress hosting (including VPS ... their websites for more detailed information. , HostMonster ... get high-powered service at a fraction of the ...
(Date:9/19/2014)... Singulair, developed by Merck, is a CysLT1 ... (LTD4). LTD4 belongs to the family of Cys-LTs, which ... mast cells and eosinophils, and which bind to the ... there are higher concentrations of Cys-LTs in the airways ... production of CysLTs is increased in asthmatics, particularly during ...
(Date:9/19/2014)... York University researchers say a simple test that ... heightened risk for developing Alzheimer,s disease in a ... signs of dementia., Faculty of Health Professor Lauren ... the study asked the participants to complete four ... screen laptop computers. The test aimed at detecting ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... a traditional Scandinavian style of eating, is ... Much like Diet Doc’s medical weight ... cooking and eating good food which leads ... focuses on teaching patients to understand how ...
(Date:9/19/2014)... 2013 NEXT Award-winning technology consultancy ... the 2014 NEXT Awards in the Technology Growth ... been selected as the sole female finalist for ... of Commerce and the Nashville Entrepreneur Center will ... of companies and individual entrepreneurs in five areas ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3
... Gardner HealthDay Reporter , WEDNESDAY, Feb. 23 (HealthDay ... that sickened about 1,500 people and claimed two lives, U.S. ... identifying sources of food contamination and preventing further infection. ... an editorial accompanying the paper in the Feb. 23 online ...
... ways to enhance athletic performance have found that bovine ... as ,leaky gut syndrome., Their findings, published in ... Physiology-Gastrointestinal and Liver Physiology , could have positive implications ... heatstroke. A research group led by Ray Playford, ...
... T-cell receptor diversity in blood samples from healthy individuals has ... published online today in Genome Research ( www.genome.org ... disease, cancer, and immune system disorders. Adaptive immunity is ... attacks cells that may be infected with viruses or contain ...
... -- How quickly and smoothly people move on from a ... relationships each partner had in earliest childhood with the people ... from the the University of Minnesota,s ongoing tracking of a ... study participants were even born. Doctoral candidate Jessica E. ...
... High-resolution images from a laser-based tool developed at Duke ... of skin cancer, while potentially saving thousands of lives and ... The tool probes skin cells using two lasers to pump ... pointer, into a suspicious mole. Scientists analyze the way the ...
... Feb. 23 (HealthDay News) -- Smoking increases the production ... shows. U.S. researchers conducted tests on human airway ... smoke suppresses a protein that causes the natural death ... The study appears online ahead of print in ...
Cached Medicine News:Health News:Fast Response Crucial in Outbreaks of Food-Borne Illness: Study 2Health News:Fast Response Crucial in Outbreaks of Food-Borne Illness: Study 3Health News:Is dairy colostrum the key to Olympic success? 2Health News:Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity 2Health News:Early Childhood Might Affect Love Life in Adult 2Health News:Lasers ID deadly skin cancer better than doctors 2Health News:Lasers ID deadly skin cancer better than doctors 3Health News:Cigarette Smoke Fuels Mucus Production in People With Bronchitis 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: